AR019692A1 - INHIBIDORES DE FACTOR DE TRANSCRIPCION NF-kB. - Google Patents

INHIBIDORES DE FACTOR DE TRANSCRIPCION NF-kB.

Info

Publication number
AR019692A1
AR019692A1 ARP990102955A ARP990102955A AR019692A1 AR 019692 A1 AR019692 A1 AR 019692A1 AR P990102955 A ARP990102955 A AR P990102955A AR P990102955 A ARP990102955 A AR P990102955A AR 019692 A1 AR019692 A1 AR 019692A1
Authority
AR
Argentina
Prior art keywords
disease
present
transcription factor
activation
diseases
Prior art date
Application number
ARP990102955A
Other languages
English (en)
Spanish (es)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR019692A1 publication Critical patent/AR019692A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP990102955A 1998-06-19 1999-06-18 INHIBIDORES DE FACTOR DE TRANSCRIPCION NF-kB. AR019692A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8982798P 1998-06-19 1998-06-19

Publications (1)

Publication Number Publication Date
AR019692A1 true AR019692A1 (es) 2002-03-13

Family

ID=22219773

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102955A AR019692A1 (es) 1998-06-19 1999-06-18 INHIBIDORES DE FACTOR DE TRANSCRIPCION NF-kB.

Country Status (21)

Country Link
US (3) US6492425B1 (enExample)
EP (1) EP1085848B1 (enExample)
JP (1) JP2002518307A (enExample)
KR (1) KR20010052991A (enExample)
CN (1) CN1311629A (enExample)
AR (1) AR019692A1 (enExample)
AT (1) ATE383769T1 (enExample)
AU (1) AU4690099A (enExample)
BR (1) BR9911152A (enExample)
CA (1) CA2335294A1 (enExample)
CO (1) CO5021213A1 (enExample)
CZ (1) CZ20004761A3 (enExample)
DE (1) DE69937997T2 (enExample)
ES (1) ES2299251T3 (enExample)
HU (1) HUP0102782A3 (enExample)
IL (1) IL140328A0 (enExample)
NO (1) NO20006451L (enExample)
PL (1) PL348969A1 (enExample)
TR (1) TR200003781T2 (enExample)
WO (1) WO1999065449A2 (enExample)
ZA (1) ZA200007447B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028424A2 (en) 1996-12-23 1998-07-02 Immunex Corporation Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
ATE412746T1 (de) 1998-05-14 2008-11-15 Immunex Corp Verfahren zur hemmung der wirkung der osteoklasten
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
EP1134221A1 (en) * 2000-03-15 2001-09-19 Aventis Pharma Deutschland GmbH Substituted beta-carbolines as lkB kinase inhibitors
FR2813315B1 (fr) 2000-08-23 2002-10-18 Genfit S A Procede d'identification de substances utiles pour le traitement de l'inflammation mettant en oeuvre l'element de reponse du recepteur ror du gene ikbalpha
UA82827C2 (en) * 2000-12-18 2008-05-26 Inhibitors against the production and release of inflammatory cytokines
ES2706902T3 (es) 2001-06-26 2019-04-01 Amgen Inc Anticuerpos para OPGL
WO2003039545A2 (en) * 2001-11-07 2003-05-15 Millennium Pharmaceuticals, Inc. Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers
US7119120B2 (en) 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
AU2003242131A1 (en) * 2002-06-05 2003-12-22 Institute Of Medicinal Molecular Design, Inc. Immunity-related protein kinase inhibitors
CN101103977A (zh) * 2002-06-05 2008-01-16 株式会社医药分子设计研究所 糖尿病治疗药
CN1658872B (zh) * 2002-06-06 2010-09-22 株式会社医药分子设计研究所 抗过敏药
CN1658855B (zh) * 2002-06-06 2010-04-28 株式会社医药分子设计研究所 O-取代羟基芳基衍生物
EA010470B1 (ru) * 2002-06-10 2008-08-29 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. ИНГИБИТОРЫ АКТИВАЦИИ NF-kB
EP1535610A4 (en) * 2002-06-10 2008-12-31 Inst Med Molecular Design Inc THERAPEUTIC CANCER
EA011707B1 (ru) * 2002-06-11 2009-04-28 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Лекарственное средство для лечения нейродегенеративных заболеваний
US7324455B2 (en) 2003-03-14 2008-01-29 International Business Machines Corporation Transfer of error-analysis and statistical data in a fibre channel input/output system
US20050004164A1 (en) * 2003-04-30 2005-01-06 Caggiano Thomas J. 2-Cyanopropanoic acid amide and ester derivatives and methods of their use
US7981915B2 (en) * 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
WO2004098510A2 (en) * 2003-04-30 2004-11-18 Beth Israel Deaconess Medical Center Cystic fibrosis therapy
US20050256132A1 (en) * 2003-04-30 2005-11-17 Wyeth Use of ER selective NF-kB inhibitors for the treatment of sepsis
BRPI0412805A (pt) * 2003-07-23 2006-09-26 Synta Pharmaceuticals Corp método para modular canais de ìon de cálcio ativado por liberação de ìon de cálcio
US7425580B2 (en) 2004-05-19 2008-09-16 Wyeth (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
WO2006117660A2 (en) * 2005-05-04 2006-11-09 Clio Pharmaceutical Corporation Method for treating cancer, coronary, inflammatory and macular disease, combining the modulation of zinc- and/or copper dependent proteins
CN100418532C (zh) * 2005-06-17 2008-09-17 吕志民 治疗多种疾病的NF-κB化合物抑制剂
US7671058B2 (en) 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
BRPI0816560A2 (pt) 2007-10-23 2015-09-01 Inst Med Molecular Design Inc Método de inibição de produção de pai-1 método para prevenção ou melhora de uma doença causada por uma super-produção de pai-1"
EP2987495A1 (en) 2007-10-25 2016-02-24 Yale University Use of phy906 as treatment for inflammatory bowel disease and/or irritable bowel syndrome
WO2009089277A2 (en) * 2008-01-08 2009-07-16 The Trustees Of The University Of Pennsylvania Rel inhibitors and methods of use thereof
US20090264514A1 (en) * 2008-04-18 2009-10-22 The Research Foundation Of State University Of New York SPHINGOMYELIN SYNTHASE 2 (SMS2) DEFICIENCY ATTENUATES NFkB ACTIVATION, A POTENTIAL ANTI-ATHEROGENIC PROPERTY
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
EP2654428B1 (en) * 2010-12-22 2018-02-14 The Trustees of Columbia University in the City of New York Histone acetyltransferase modulators and usese thereof
TWI492920B (zh) * 2012-04-18 2015-07-21 Nat Defense Medical Ct 水楊酸苯胺衍生小分子之醫藥組合物及其製備與醫藥用途
US9562002B2 (en) 2013-01-15 2017-02-07 Board Of Regents, The University Of Texas System STAT3 inhibitor
EP3036005A4 (en) 2013-08-21 2017-04-26 The Board Of Regents Of The University Of Texas System Compositions and methods for targeting connexin hemichannels
EP3126332A4 (en) 2014-03-31 2017-09-06 The Trustees of Columbia University in the City of New York Histone acetyltransferase activators and uses thereof
EP3967312A1 (en) 2014-09-12 2022-03-16 UNION therapeutics A/S Antibacterial use of halogenated salicylanilides
CN105797154B (zh) * 2014-12-31 2020-03-10 中国科学院上海生命科学研究院 软骨干细胞的分离及其应用
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
WO2017122209A2 (en) * 2016-01-12 2017-07-20 Yeda Research And Development Co. Ltd. NF-kappaB INHIBITORS
WO2017147561A1 (en) 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System CONNEXIN (Cx) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF
GB201604484D0 (en) 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
CA3057284A1 (en) 2017-03-21 2018-09-27 Novalead Pharma Inc. Therapeutic agent for phosphodiesterase inhibition and its related disorders
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
BR112022009457A2 (pt) * 2019-11-18 2022-08-16 Univ California Inibidores duplos de receptor androgênico/akr1c3

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1079177A (en) * 1963-06-11 1967-08-16 Stecker Internat S P A Improvements in pesticide composition for destroying internal worm parasites in animals
GB1079178A (en) * 1966-07-27 1967-08-16 Stecker Internat S P A Improvements in pesticide compositions for destroying internal worm parasites in animals
US4742083A (en) * 1983-08-24 1988-05-03 Lever Brothers Company Method of relieving pain and inflammatory conditions employing substituted salicylamides
US4803279A (en) 1985-05-23 1989-02-07 Smithkline Beckman Corporation 1.4-dihydro-4-pyridyl-substituted imidazo (2,1-b) thiazoles and the corresponding thiazines.
JPH06500112A (ja) * 1990-08-21 1994-01-06 ジ・アップジョン・カンパニー 抗関節炎剤としてのビスホスホン酸誘導体
EP0584238A1 (en) * 1991-05-17 1994-03-02 Chiron Corporation INHIBITOR OF NF-$g(k)B TRANSCRIPTIONAL ACTIVATOR AND USES THEREOF
US5466715A (en) * 1991-12-31 1995-11-14 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
DE4200534A1 (de) * 1992-01-11 1993-07-15 Henkel Kgaa Neue n-benzyl-4-aminophenole und deren verwendung als entwicklerkomponente in oxidationshaarfaerbemitteln
ZA944191B (en) * 1993-06-15 1995-02-08 Univ Australian Synergistic anthelmintic compositions
EP1005347A4 (en) * 1997-08-06 2002-08-28 Smithkline Beecham Corp ANTAGONISTS OF THE RECEPTORS OF THE MONOCYTE MACROPHAGE FOR USE IN TREATING CARDIOVASCULAR DISEASES

Also Published As

Publication number Publication date
JP2002518307A (ja) 2002-06-25
US20030092771A1 (en) 2003-05-15
HUP0102782A3 (en) 2002-12-28
TR200003781T2 (tr) 2001-07-23
ATE383769T1 (de) 2008-02-15
EP1085848B1 (en) 2008-01-16
NO20006451D0 (no) 2000-12-18
EP1085848A4 (en) 2004-09-08
CA2335294A1 (en) 1999-12-23
NO20006451L (no) 2000-12-18
WO1999065449A2 (en) 1999-12-23
ZA200007447B (en) 2002-02-13
US20060035979A1 (en) 2006-02-16
BR9911152A (pt) 2001-03-06
US6492425B1 (en) 2002-12-10
CN1311629A (zh) 2001-09-05
DE69937997T2 (de) 2009-02-19
ES2299251T3 (es) 2008-05-16
WO1999065449A3 (en) 2000-03-30
EP1085848A2 (en) 2001-03-28
CO5021213A1 (es) 2001-03-27
IL140328A0 (en) 2002-02-10
CZ20004761A3 (cs) 2001-08-15
WO1999065449A8 (en) 2001-03-08
HUP0102782A2 (hu) 2001-12-28
AU4690099A (en) 2000-01-05
PL348969A1 (en) 2002-06-17
DE69937997D1 (enExample) 2008-03-06
KR20010052991A (ko) 2001-06-25

Similar Documents

Publication Publication Date Title
AR019692A1 (es) INHIBIDORES DE FACTOR DE TRANSCRIPCION NF-kB.
Rauf et al. Honokiol: A review of its pharmacological potential and therapeutic insights
Zhang et al. Morinda officinalis How.–A comprehensive review of traditional uses, phytochemistry and pharmacology
EA200500250A1 (ru) Аналоги тиомолибдата и их применение
UY27173A1 (es) Quinazolinas como inhibidores de mmp-13
ECSP044998A (es) Pirrolo pirimidinas como agentes para la inhibicion de proteasas de cisteina
ES2192192T3 (es) Dieteres de catecol como inhibidores selectivos de pde iv.
ECSP077231A (es) Antagonistas de vla-4 multivalentes que comprenden porciones de polietilenglicol
CY1109194T1 (el) Παραγωγα ν-υδροξυαμιδιου και η χρηση του
UY27167A1 (es) Inhibidores de piridina de metaloproteinasas de la matriz
ATE331718T1 (de) Spirosubstituierte pyrrolopyrimidine
MX9702731A (es) Compuestos de benzopirano y benzo fusionados, composiciones que los contienen y uso de los mismos.
ITMI20031311A1 (it) Formulazioni per il trattamento di disturbi artrosici.
PA8529701A1 (es) Compuestos retinoides
CR6606A (es) 5-cloro-3-(4-metanosulfonilfenil)-6-metil[2,3 ]-bipiridinil en forma cristalina pura y proceso para su sintesis
ES2172695T3 (es) Carboxamidas y sulfonamidas de benzofurano.
UY27915A1 (es) Nuevos conjugados de efectores, procedimientos para su preparación y su uso farmacéutico.
BR0212661A (pt) Compostos de pirazolil benzenossulfamida substituìdos para o tratamento de inflamação
ATE438618T1 (de) Inhibitoren von humanem adam-10
AR003473A1 (es) Uso de la l-carnitina o una acil l-carnitina en donde el acilo es seleccionado del grupo que comprende acetilo, propionilo, butirilo, valerilo e isovalerilo, o de una sal farmacologicamente aceptable de las mismas para la produccion de un medicamento
BR9911151A (pt) Inibidores do fator de transcrição nf-kb
ECSP003707A (es) Diazepanes
SV1997000036A (es) Inhibisores de matrices metaloproteasas mediante acidos biaril oxobutiricos sustituidos
EA200300954A1 (ru) Прегабалин-лактозные конъюгаты
ES2163634T3 (es) Benzopiranos y composiciones farmaceuticas que les contienen.